| High frequency of mutations of the PIK3CA gene in human cancers Y Samuels, Z Wang, A Bardelli, N Silliman, J Ptak, S Szabo, H Yan, ... Science, 2004 | 3761 | 2004 |
| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 3162 | 2014 |
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2188 | 2010 |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 2050 | 2016 |
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer F Di Nicolantonio, M Martini, F Molinari, A Sartore Bianchi, S Arena, ... | 1991 | 2008 |
| International network of cancer genome projects International Cancer Genome Consortium Nature 464 (7291), 993, 2010 | 1805 | 2010 |
| Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR A Prahallad, C Sun, S Huang, F Di Nicolantonio, R Salazar, D Zecchin, ... Nature 483 (7387), 100-103, 2012 | 1723 | 2012 |
| Liquid biopsies: genotyping circulating tumor DNA LA Diaz Jr, A Bardelli Journal of clinical oncology 32 (6), 579, 2014 | 1714 | 2014 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012 | 1611 | 2012 |
| RAF/RAS oncogenes and mismatch-repair status H Rajagopalan, A Bardelli, C Lengauer, KW Kinzler, B Vogelstein, ... Nature 418 (6901), 934-934, 2002 | 1459 | 2002 |
| Liquid biopsy: monitoring cancer-genetics in the blood E Crowley, F Di Nicolantonio, F Loupakis, A Bardelli Nature reviews Clinical oncology 10 (8), 472-484, 2013 | 1350 | 2013 |
| A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family C Ponzetto, A Bardelli, Z Zhen, F Maina, P dalla Zonca, S Giordano, ... Cell 77 (2), 261-271, 1994 | 1137 | 1994 |
| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ... The lancet oncology 6 (5), 279-286, 2005 | 1114 | 2005 |
| Integrating liquid biopsies into the management of cancer G Siravegna, S Marsoni, S Siena, A Bardelli Nature reviews Clinical oncology 14 (9), 531-548, 2017 | 1027 | 2017 |
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ... Cancer research 67 (6), 2643-2648, 2007 | 985 | 2007 |
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ... Cancer research 69 (5), 1851-1857, 2009 | 843 | 2009 |
| A phosphatase associated with metastasis of colorectal cancer S Saha, A Bardelli, P Buckhaults, VE Velculescu, C Rago, BS Croix, ... Science 294 (5545), 1343-1346, 2001 | 829 | 2001 |
| Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. L Naldini, KM Weidner, E Vigna, G Gaudino, A Bardelli, C Ponzetto, ... The EMBO journal 10 (10), 2867-2878, 1991 | 792 | 1991 |
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 787 | 2015 |
| A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011 | 771 | 2011 |
